Myriad Genetics ( (MYGN) ) has shared an update.
Myriad Genetics has resolved a series of shareholder derivative lawsuits alleging fiduciary breaches by former and current directors. The settlement, approved by the Delaware Court, includes corporate governance reforms and a $950,000 attorney fee award, with no admission of wrongdoing by the parties involved. This agreement may reassure investors, highlighting efforts to strengthen oversight and governance within the company.
For a thorough assessment of MYGN stock, go to TipRanks’ Stock Analysis page.